• Earlier this month, Humana announced expanded value-based cardiac care partnerships with CVAUSA’s Novocardia, Karoo Health, US Heart and Vascular and Chamber Cardio, giving eligible Medicare Advantage members in multiple states access to enhanced remote monitoring, 24/7 support and coordinated cardiology care.
• This broadened heart-health program underscores Humana’s emphasis on value-based care for chronic conditions, aiming to improve outcomes while reducing avoidable hospital stays for its Medicare Advantage population.
• Next, we’ll examine how this expansion of value-based cardiac care for Medicare Advantage members may influence Humana’s broader investment narrative.

This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

Humana Investment Narrative Recap

To own Humana, you need to believe its Medicare Advantage focus and value-based care programs can support earnings despite regulatory, cost and utilization pressures. The near term hinge point remains how effectively Humana manages medical costs and Stars-related uncertainty, while a key risk is ongoing regulatory and reimbursement changes that could pressure margins. The latest shareholder proposal on executive severance and the new junior subordinated notes do not appear to materially change this near term setup.

The most relevant recent development here is Humana’s expanded value-based cardiac care program for Medicare Advantage members, which reinforces the core catalyst of improving clinical quality and medical cost control for high risk populations. While consensus analysts were already watching value-based models and Stars performance as drivers of future earnings, this heart health expansion highlights how much of Humana’s thesis rests on making these programs work at scale for complex, chronic conditions.

But while this care model offers potential upside, investors should also be aware of how shifting reimbursement rules could affect...

Humana's narrative projects $150.9 billion revenue and $3.3 billion earnings by 2028.

Uncover how Humana's forecasts yield a $223.88 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Lowest estimate analysts take a more cautious view than consensus, assuming revenue at about US$129.7 billion and earnings of roughly US$2.4 billion by 2028, and their concerns about Medicare Advantage reimbursement and margin compression could interact with this new value based cardiac push in ways that change both narratives over time.

Explore 11 other fair value estimates on Humana - why the stock might be worth over 5x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Humana research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.